Project Grant HT94252410863
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$484K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $1,016,449.00 Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports single-cell studies of immune-mediated injury and immunoregulation in human vascular composite allograft (VCA) rejection, with a performance period from August 1, 2024 to July 31, 2027. The award was granted to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in...
The Defense Health Agency awarded a $499,998.00 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "Identifying Biomarkers of Human VCA Rejection to Enable Noninvasive Diagnostic Testing." This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public. The research project at Brigham &...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
This $178,999 federal Project Grant, awarded on May 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Brigham & Women's Hospital Inc. to target TFE3 fusion proteins using PROTAC (Proteolysis Targeting Chimera) in translocation renal cell carcinoma (TRCC). The research aims to transform healthcare for military service members, veterans, and the broader public by developing innovative medical solutions. Brigham...
This federal Project Grant award, valued at $654,273.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research to develop innovative variable ventilation approaches to reduce ventilator-induced lung injury in patients with acute respiratory distress syndrome (ARDS). The primary awardee is Brigham & Women's Hospital Inc., which is a prominent academic medical center and research institution in Boston,...
This federal Project Grant award of $999,999.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports advanced biomedical research by Brigham & Women's Hospital, a prominent academic medical center and research institution, to investigate EBV signatures in relapsing and progressive forms of multiple sclerosis. The research project will be conducted over a period of approximately 3 years, from Aug 1, 2025 to...
The Department of Defense's Defense Health Agency awarded a $992,302 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, which runs from September 15, 2025 to September 14, 2028, will support research aimed at "Targeting MHCII Ubiquitination to Induce Immune Regulation in Vascularized Composite Tissue Transplantation." MGH, a renowned non-profit...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
The Defense Health Agency awarded a $899,999 Project Grant to Wake Forest University Health Sciences under the Military Medical Research and Development program (CFDA 12.420) to develop a novel point-of-care assay for monitoring rejection and immunosuppression in vascularized composite allotransplantation (VCA) recipients. The project aims to transform healthcare for service members and the public through innovative biomedical research focused on medical solutions for the battlefield. The...
This Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) in the amount of $793,572.00 is effective August 15, 2024 and runs through August 14, 2027. The award has been transferred from the General Hospital Corporation to Brigham and Women's Hospital Inc. in Boston, MA. The grant will fund a research project titled "A NOVEL TRANSLATIONAL MECHANISM UNDERLYING TSC PATHOPHYSIOLOGY". Brigham and Women's Hospital, a prominent...